Publication details

Efficacy and safety of novel temperature-controlled radiofrequency ablation system during pulmonary vein isolation in patients with paroxysmal atrial fibrillation: TRAC-AF study

Authors

STÁREK Zdeněk LEHAR František JEŽ Jiří PEŠL Martin NEUZIL Petr SEDIVA Lucie PETRU Jan DUJKA Libor FUNASAKO Moritoshi KAUTZNER Josef PEICHL Petr ALDHOON Bashar ALBENQUE Jean-Paul COMBES Stephane BOVEDA Serge DUKKIPATI Srinivas R. REDDY Vivek Y.

Year of publication 2022
Type Article in Periodical
Magazine / Source Journal of interventional cardiac electrophysiology
MU Faculty or unit

Faculty of Medicine

Citation
web https://link.springer.com/article/10.1007%2Fs10840-021-00986-0
Doi http://dx.doi.org/10.1007/s10840-021-00986-0
Keywords Catheter radiofrequency ablation; Atrial fibrillation; Diamond tip irrigated catheter; Temperature contol ablation; High-resolution electrograms; Safety and efficacy
Description Background and purpose Saline-irrigated radiofrequency ablation (RFA) for atrial fibrillation (AF) is limited by the absence of reliable thermal feedback limiting the utility of temperature monitoring for power titration. The DiamondTemp (DT) ablation catheter was designed to allow efficient temperature-controlled irrigated ablation. We sought to assess the 1-year clinical safety and efficacy of the DT catheter in treating drug-refractory paroxysmal AF. Methods The TRAC-AF trial (NCT02821351) is a prospective, multi-center (n = 4), single-arm study which enrolled patients with symptomatic, drug-refractory, paroxysmal AF. Using the DT catheter, point-by-point ablation was performed around all pulmonary veins (PVs) to achieve PV isolation (PVI). Ablation was performed in a temperature-controlled mode (60 degrees C, max 50 W). Acute and chronic efficacy and safety was evaluated. Results Seventy-one patients (age 69.9 +/- 11.0 years; 60.6% male) were ablated using the DT catheter. The mean fluoroscopy and RF ablation times were 9.3 +/- 6.1 min and 20.6 +/- 8.9 min, respectively. Acute isolation of all PVs was achieved in 100% of patients, and freedom from AF after 1 year was 70.6%. There were no steam pops, char, or coagulum on the catheter tip after ablation. There were few serious procedure/device-related adverse events including a single case of cardiac tamponade (1.4%) and transient ischemic attack (1.4). Conclusion This first inman series demonstrates that temperature-controlled irrigated RFA with the DT catheter is efficient, safe, and effective in the treatment of paroxysmal AF. Randomized controlled trials are ongoing and will evaluate better the role of this catheter in relation to standard RFA.

You are running an old browser version. We recommend updating your browser to its latest version.

More info